22:46 , Apr 16, 2019 |  BC Extra  |  Preclinical News

Mounting a mitochondrial attack to starve the inflammasome

While companies are directly inhibiting NLRP3 to treat a swath of inflammatory diseases, at least one academic group is shutting down the protein’s upstream mitochondrial triggers. The approach, from University of California San Diego researchers,...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Choline kinase-a (CHKA) In vitro studies identified a CHKA inhibitor that could help treat cancers. An asymmetrical, biscationic inhibitor of...
07:00 , Oct 22, 2012 |  BioCentury  |  Emerging Company Profile

Sprint: Quick start in cancer

Sprint Bioscience AB is leveraging its founders' expertise in fragment-based drug discovery and structural biology to generate leads against novel cancer metabolism and autophagy targets. The biotech hopes to out-license its therapeutics when the molecules...
00:51 , Jul 2, 2010 |  BC Extra  |  Financial News

Advanced Cancer Therapeutics raises $10 million

Advanced Cancer Therapeutics LLC (Louisville, Ky.) raised $10 million in seed financing from undisclosed high net-worth individuals and institutions in Kentucky. The company has three lead programs to treat cancer: small molecule inhibitors for 6-phosphofructo-2-kinase...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Advanced Cancer Therapeutics preclinical data

Researchers at the University of Louisville published in Oncogene that selective inhibition of choline kinase (CHK) expression simultaneously attenuated two cellular signaling pathways required for cancer cell growth and survival - the mitogen activated protein...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer received exclusive, worldwide rights from the university's James Graham Brown Cancer Center to develop and commercialize CK37 . The small molecule inhibitor of choline kinase (CHK) is in preclinical testing for cancer. The...
07:00 , Oct 9, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Narcolepsy Carnitine palmitoyltransferase 1B (muscle) (CPT1B); choline kinase-b (CHKB); SNP rs5770917 A genome-wide association study identified a SNP located between...
07:00 , Apr 12, 2004 |  BioCentury  |  Strategy

Exelixis: Act III

Exelixis Pharmaceuticals Inc. is one of a handful of companies that has successfully made the transition from a functional genomics company to a fully fledged drug development company. EXEL has metamorphosed in three stages, raising...
08:00 , Jan 20, 1997 |  BC Week In Review  |  Company News

Israel Deaconess Medical Center other research news

Researchers published findings on a gene that may be involved in limiting the growth of cancer cells by blocking oncogene activity. In The Journal of Biological Chemistry, the researchers reported that the CHK gene is...